Alopecia areata, an autoimmune disorder characterized by non-scarring hair loss, has long posed significant challenges for patients and clinicians alike.
With a difficult-to-predict disease course and a significant impact on physical and emotional well-being, patients have faced limited treatment options that often failed to address the underlying mechanisms of the condition.
Until recently, the therapeutic landscape for alopecia areata was defined by off-label treatments with inconsistent efficacy and safety profiles. The approval of targeted therapies, namely baricitinib (Olumiant), ritlecitinib (Litfulo), and deuruxolitinib (Leqselvi), marks a transformative shift in care, providing evidence-based options for those with the disease. These approvals also underscore the growing recognition of alopecia areata as a…